Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ATP4A | P20648 | 5/20 | 0.31 |
| ▸ | ATP4B | P51164 | 5/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899191 | 0.85 | KDM4E (0.33) | ALDH1A1 | |
| SCHEMBL22186701 | 0.81 | HTR1B (0.33) | HTR1BATP4AATP4BFDPSTHRB | |
| SCHEMBL1132445 | 0.81 | TSHR (0.43) | TSHRTDP1ALDH1A1 | |
| SCHEMBL26117749 | 0.79 | HTR1B (0.37) | HTR1BATP4AATP4BHTR1DFDPS | |
| SCHEMBL11199398 | 0.79 | TSHR (0.44) | TSHRTDP1ALDH1A1THRBGAA | |
| SCHEMBL320429 | 0.78 | TSHR (0.39) | TSHRTDP1ALDH1A1 | |
| SCHEMBL7783969 | 0.77 | TSHR (0.48) | TSHRTDP1ALDH1A1THRBMAPT | |
| SCHEMBL9897525 | 0.77 | MAPT (0.33) | MAPT | |
| SCHEMBL7787426 | 0.77 | TSHR (0.48) | TSHRTDP1ALDH1A1THRBMAPT | |
| SCHEMBL3588297 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150595-B2 | Process for producing silane coupling agent | BRIDGESTONE CORPORATION (JP) | 2015-10-06 | — | — | US | claimed |
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | claimed |
| EP-2471798-A1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | Bridgestone Corporation (JP) | 2012-07-04 | — | — | EP | claimed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | claimed |
| US-9150595-B2 | Process for producing silane coupling agent | BRIDGESTONE CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2471798-B1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | BRIDGESTONE CORP (JP) | 2015-08-19 | — | — | EP | disclosed |
| EP-2471798-A1 | PROCESS FOR PRODUCTION OF SILANE COUPLING AGENTS | Bridgestone Corporation (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | BRIDGESTONE CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149929-A1 | PROCESS FOR PRODUCING SILANE COUPLING AGENT | HAO2, SAMM50, SKP2 | HTR1B 3736/4885TSHR 4663/4885TDP1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.